Merck & Co., Inc. (MRK) Starts Phase 3 Trial of OHTUVAYRE for COPD Exacerbations

What happened

Merck began enrolling patients in ENHANCE-3, a Phase 3 trial testing OHTUVAYRE plus standard care to prevent COPD exacerbations, or worsening episodes of the lung disease. The study plans to include about 2,136 patients across 28 countries; its primary measure is the annual rate of moderate or severe exacerbations.

Confirmed

Global impact / market context

The trial tests whether OHTUVAYRE can prevent worsening episodes in addition to its existing role in COPD maintenance treatment. Positive results could support a broader use and future revenue, while unsuccessful results could limit that opportunity; the article provides no results or sales estimates.

Analyst inference

OHTUVAYRE was approved by the FDA for COPD maintenance treatment in June 2024, so this study extends development of an existing product rather than introducing a new medicine. However, enrollment alone does not establish effectiveness, safety, regulatory approval for prevention, or commercial demand.

Confirmed

What to watch

1. Track enrollment in the planned 2,136-patient study across 28 countries; delays or changes to the trial could postpone the evidence needed to assess the prevention use. Analyst inference
2. Watch for trial results on the annual rate of moderate or severe exacerbations, the main measure of whether OHTUVAYRE adds benefit beyond standard care. Confirmed
3. Merck says it will share results with regulatory authorities globally; subsequent regulatory decisions would determine whether the tested prevention use can be approved. Confirmed

Evidence

• Original source link unavailable